JAK Inhibitors for Eczema
What are oral JAK inhibitors?
JAK inhibitors are targeted medications that affect signaling pathways involved in inflammation. In eczema, they may be used either as topical treatment or as oral treatment depending on the medication and the clinical situation.
They have become an important part of the treatment landscape because they can work more directly on pathways involved in itch and inflammation. Beyond their current indications, JAK inhibitors are also in use for other dermatological conditions like vitiligo and alopecia areata.
Which JAK inhibitors are used in eczema?
JAK-related treatments used in dermatology for eczema include:
Ruxolitinib cream (Opzelura), a topical option
Upadacitinib (Rinvoq), an oral option
Delgocitinib (Anzupgo), a topical option used in chronic hand eczema
Abrocitinib (Cibinqo), an oral option
Not every JAK-related therapy is interchangeable, and each has its own role, side-effect considerations, and treatment setting.
What are possible side effects of oral JAK inhibitors?
Topical and oral JAK inhibitors have very different risk profiles.
Topical JAK inhibitors may cause:
Application-site irritation
Acne-like bumps
Mild local discomfort
Oral JAK inhibitors may involve broader risks and can require more careful pretreatment review. Possible issues can include:
Infections
Acne, nausea, or headache
Lab abnormalities
Blood clot, cardiovascular, or other more serious warnings in selected patients
Your dermatologist will review whether a topical or oral approach makes the most sense for your situation.
How are oral JAK inhibitors used?
Topical JAK inhibitors are applied to the skin as directed, usually to limited affected areas. Oral JAK inhibitors are taken by mouth on a schedule directed by your provider and are generally reserved for patients with more significant disease.
These medications are typically part of a broader eczema treatment plan that also includes skin-barrier care, trigger reduction, and other topical or systemic therapies when needed.